Congestive Heart Failure
&nbsp;
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes shortness of breath and fatigue (tiredness), and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.
&nbsp;
&nbsp;
Congestive Heart Failure Epidemiology Segmentation
<ul>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Population of Heart Failure
</li>
<li dir="ltr" aria-level="1">
Gender-specific Diagnosed Prevalent Population of Heart Failure
</li>
<li dir="ltr" aria-level="1">
Ejection Fraction&ndash;specific Diagnosed Prevalent Population of Heart Failure
</li>
<li dir="ltr" aria-level="1">
New York Heart Association (NYHA) Class-specific Diagnosed Prevalent Population of Heart Failure
</li>
<li dir="ltr" aria-level="1">
Type-specific Diagnosed Prevalent Population of Heart Failure
</li>
<li dir="ltr" aria-level="1">
Age-specific Diagnosed Prevalent Population of Heart Failure
</li>
</ul>
Congestive Heart Failure Epidemiology
<ul>
<li dir="ltr" aria-level="1">
Across the 7 Major Markets (7MM), the total diagnosed prevalent population of heart failure was estimated at approximately 21.6 million cases in 2025.
</li>
<li dir="ltr" aria-level="1">
The EU4 and the UK accounted for 40% of diagnosed cases, followed by the United States (35%) and Japan (25%).
</li>
<li dir="ltr" aria-level="1">
Congestive heart failure remains one of the leading causes of hospitalization among individuals aged over 65 years, creating a substantial clinical and economic burden across healthcare systems.
</li>
<li dir="ltr" aria-level="1">
In the United States, HFpEF represented 61% of diagnosed heart failure cases, followed by HFrEF (29%) and HFmrEF (10%). Gender-specific analysis showed that males accounted for approximately 60% of diagnosed cases, while females represented 40%.
</li>
</ul>
Congestive Heart Failure Market
<ul>
<li dir="ltr" aria-level="1">
Within the 7 Major Markets (7MM), the United States captured the largest share of the congestive heart failure treatment market in 2025, accounting for nearly 72% of the total market share.
</li>
<li dir="ltr" aria-level="1">
The CHF market size across the 7MM was estimated at approximately USD 9 billion in 2025.
</li>
<li dir="ltr" aria-level="1">
The market is expected to expand significantly during the forecast period (2022&ndash;2036), driven by increasing disease prevalence, expanding treatment adoption, and the launch of novel therapies targeting multiple heart failure subtypes.
</li>
</ul>
Congestive Heart Failure Market Drivers
<ul>
<li dir="ltr" aria-level="1">
The growing global burden of cardiovascular disease, aging populations, and increasing prevalence of diabetes, obesity, and hypertension are major contributors driving growth in the CHF market.
</li>
<li dir="ltr" aria-level="1">
The strong clinical adoption of SGLT inhibitors, including therapies such as INPEFA, JARDIANCE, and FARXIGA, has significantly transformed the heart failure treatment landscape across all ejection fraction categories.
</li>
<li dir="ltr" aria-level="1">
Ongoing development and commercialization of emerging therapies aimed at improving cardiac function, reducing hospitalization risk, and slowing disease progression are expected to accelerate market growth.
</li>
</ul>
Congestive Heart Failure Market Barriers
<ul>
<li dir="ltr" aria-level="1">
Despite advancements in therapy, heart failure remains a chronic progressive disease with no definitive cure, and many patients continue to deteriorate despite optimized standard-of-care treatment.
</li>
<li dir="ltr" aria-level="1">
Delayed diagnosis and inadequate disease monitoring often result in advanced-stage presentation, reducing the effectiveness of therapeutic intervention.
</li>
<li dir="ltr" aria-level="1">
Differences in healthcare reimbursement policies and pricing environments across regions, particularly between the United States and Europe, may limit patient access to innovative therapies.
</li>
</ul>
Emerging Congestive Heart Failure Drugs
<ul>
<li dir="ltr" aria-level="1">
Omecamtiv mecarbil
</li>
<li dir="ltr" aria-level="1">
CardiAMP Cell Therapy
</li>
<li dir="ltr" aria-level="1">
CRD-740
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
Key Congestive Heart Failure Companies
<ul>
<li dir="ltr" aria-level="1">
Lexicon Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Viatris
</li>
<li dir="ltr" aria-level="1">
American Regent
</li>
<li dir="ltr" aria-level="1">
Vifor
</li>
<li dir="ltr" aria-level="1">
Daiichi Sankyo
</li>
<li dir="ltr" aria-level="1">
scPharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Boehringer Ingelheim
</li>
<li dir="ltr" aria-level="1">
Eli Lilly
</li>
<li dir="ltr" aria-level="1">
AstraZeneca
</li>
<li dir="ltr" aria-level="1">
Cytokinetics
</li>
<li dir="ltr" aria-level="1">
BioCardia
</li>
<li dir="ltr" aria-level="1">
Cardurion Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
&nbsp;

Congestive Heart Failure Market Infographic

Congestive Heart Failure Infographics

Congestive Heart Failure Market

Congestive Heart Failure Market Infographic provides insights into the Market Size, Share, Trends, Treatment, Epidemiology, Key Companies, and Emerging Therapies 